Q3 2024

Source filing unavailable

Q3 2024 · —

Revenue

$307.00M

no prior Q3 2023 on file

Net Income

$22.00M

no prior Q3 2023 on file

EPS Diluted

$0.16

no prior Q3 2023 on file

Gross Profit$241,000,000—

Operating Income$35,000,000—

Operating Cash Flowderived

Same quarter

no prior Q3 2023 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Indivior Pharmaceuticals, Inc. · CIK 1625297 · Engraved from SEC EDGAR